LXRX Q2 2025 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+1652.6% YoY

Gross Profit

$29M99.3% margin

Operating Income

$4M12.9% margin

Net Income

$3M11.3% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+2187.3%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$226M

Total Liabilities

$96M

Stockholders' Equity

$129M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$2M	+1652.6%
Gross Profit	$29M	$1M	+1835.0%
Operating Income	$4M	-$55M	+106.7%
Net Income	$3M	-$53M	+106.1%

Revenue Segments

License

$28M95%

Product

$1M5%